MedTrace Logo

Algorithm for Predicting the Unfavorable Course of Sepsis in Children

NCT05908162 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 185

Last updated 2025-12-30

Study results available
· View outcomes & findings →

Summary

A comprehensive strategy will be used to investigate the relationship and correlation between 4 diagnostically significant markers relevant for early diagnosis and prediction of complications and death in the development of sepsis in children (C-reactive protein, procalcitonin, presepsin and lipopolysaccharide binding protein). For the first time, an attempt will be made to assess the genetic characteristics of the patient's from the point of view of predisposition to the unfavorable development of the sepsis based on the study of polymorphism of a number of genes of the immune system (tumor necrosis factor beta; interleukin 6, 8, 10; lymphotoxin alpha, etc.).

Based on the study results, an algorithm to predict the unfavorable course of sepsis in children will be developed using a comprehensive assessment of biochemical and molecular genetic markers.

Conditions

Interventions

DIAGNOSTIC_TEST

Bood leukocyte subsets

Determination of blood leukocyte subpopulations, subpopulation of monocytes and expression CD64 on neutrophils

Sponsors & Collaborators

  • Belarusian State Medical University

    collaborator OTHER

  • The Republican Research and Practical Center for Epidemiology and Microbiology

    lead OTHER

Principal Investigators

  • Elena G Fomina, Dr · The Republican Research and Practical Center for Epidemiology and Microbiology (RRPCEM)

Eligibility

Min Age
1 Day
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2024-12-25
Completion
2025-01-01

Countries

  • Belarus

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05908162 on ClinicalTrials.gov